Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Source document

Untitled source document

No live link available for this source.

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

Over the last three years, approximately 20 million people have been diagnosed and treated for severe Type I allergic reactions that may lead to anaphylaxis in the United States
80% confidence
For chronic spontaneous urticaria, 6.5 million people are estimated to be diagnosed and treated with antihistamines or biologics today in China
80% confidence
The approval of neffy in China represents a significant advancement for the millions of patients and caregivers managing severe allergic reactions whose only option until now was to seek emergency medical help without the option to self-administer epinephrine in a community setting
80% confidence
ARS Pharma and Pediatrix Therapeutics anticipate filing for approval of neffy 1 mg dose for children greater than 15 kg and less than 30 kg in the coming months
80% confidence
This innovation can meaningfully improve preparedness, confidence, and outcomes for patients and families across China
80% confidence
Approximately 4.0% to 8.2% of the population of China (about 50 to 100 million people) is estimated to be affected by food allergies and at risk for severe allergic reactions
80% confidence
Of those who filled prescriptions, only half consistently carry their prescribed auto-injector
80% confidence
More than half of patients or caregivers who carry an auto-injector either delay or do not administer the device when needed in an emergency
80% confidence
Approval in New Zealand is expected by the end of 2025
80% confidence
There are approximately 40 million people in the United States who experience Type I allergic reactions
80% confidence
In 2023, only 3.2 million filled their active epinephrine auto-injector prescription in the United States
80% confidence
As the first community use epinephrine product available in the Chinese market, neffy has the potential to transform how severe allergies are treated, enabling earlier epinephrine use at the first signs of symptoms and reducing barriers that can delay care
80% confidence